(218 days)
No
The description focuses on the material properties, manufacturing process based on physical impressions, and clinical performance related to lens fit and ocular health, with no mention of AI or ML for design, analysis, or manufacturing.
No.
Explanation: The device is indicated for the correction of refractive errors and management of irregular corneal conditions, which are not considered therapeutic treatments but rather correctional or management tools.
No
The device is a contact lens designed to correct refractive errors and manage irregular corneal conditions; it does not diagnose medical conditions.
No
The device description clearly states it is a rigid gas permeable (RGP) lens manufactured from physical materials (roflufocon D) and involves a physical impression process using vinyl polysiloxane (VPS) material. It is a physical medical device, not software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use is for the correction of refractive error and management of irregular corneal conditions. This is a therapeutic and corrective function, not a diagnostic one.
- Device Description: The device is a contact lens that acts as a refracting medium. It is a physical device placed on the eye to alter light focus.
- Lack of Diagnostic Function: There is no mention of the device being used to analyze samples (blood, tissue, etc.) or to provide information for the diagnosis of a disease or condition.
- Anatomical Site: While the device interacts with the ocular surface, cornea, and retina, its purpose is to correct vision, not to diagnose conditions of these structures through analysis of biological samples.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. This device does not fit that description.
N/A
Intended Use / Indications for Use
The EyePrintPRO (roflufocon D) Scleral GP Lenses are indicated for daily wear for the correction of refractive error in aphakic and not aphakic persons with myopia or hyperopia. The lenses may be prescribed in otherwise non-diseased eyes that require a rigid gas permeable lens for the management of irregular corneal conditions such as; keratoconus, pellucid marginal degeneration or following penetrating keratoplasty or refractive (e.g. LASIK) surgery.
Eyecare practitioners may prescribe the lenses for frequent/planned replacement wear, with cleaning, disinfection and scheduled replacement. When prescribed for frequent wear, the lens may be cleaned and disinfected using a chemical (not heat) lens care system.
Product codes (comma separated list FDA assigned to the subject device)
HQD
Device Description
The EvePrintPRO (roflufocon D) Scleral GP Lens is a rigid gas permeable (RGP) lens designed from measurements of the ocular surface obtained by the EyePrint Impression Process. The vinyl polysiloxane (VPS) impression material used for the EyePrint Impression process is Panasil Initial Contact Light, with 510(k) clearance under K083701. The lenses are manufactured from the hydrophobic contact lens material (roflufocon D). When placed on the human cornea, the EvePrintPRO RGP lenses act as a refracting medium to focus light rays upon the retina.
The EyePrintPRO (roflufocon D) Scleral GP Lenses are available as lathe cut lenses manufactured from (roflufocon D) optical blanks, which incorporate a handling tint using the following FDA listed color additives: D & C Green No. 6, FD & C Red No. 17, CI Solvent Yellow 18.
In the EyePrintPRO (roflufocon D) Scleral GP Lenses with UV Blocker, a Benzophenone UV absorbing monomer is used to block UV radiation. The UV Blocker is 2,2'-Dihydroxy-4,4'dimethoxybenzophenone.
The UV blocking for EyePrintPRO (roflufocon D) Scleral GP Lenses averages > 98% in the UVB range of 280nm - 315nm and 95% in the UVA range of 316 - 380nm.
The physical and mechanical properties of the lens are:
Refractive Index 1.4333
Light Transmission (clear) greater than 97%
Light Transmission (tinted) greater than 90%
Wetting Angle 3°
Specific Gravity 1.166
Oxygen Permeability 100 x 10-11 (cm²/sec)(mlO₂)/(ml x mmHg @ 35°C)
Flexural Strength (Mpa) 49.0
Modulus (Mpa) 76.7
Shore D Hardness 77.5
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
ocular surface, human cornea, eyes, retina
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Eyecare practitioners
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Bioburden testing was performed on rigid gas permeable lenses manufactured at the Advanced Vision Technologies facility. Testing resulted in less than 1 colony forming units (CFU) per lens. The acceptance criteria is less than 100 CFU per lens.
Non-invasive tear break up time (NITBUT), ocular surface redness, and corneal staining were evaluated (n = 8) before and after the EyePrint Impression Process. No significant changes from baseline were observed.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.5916 Rigid gas permeable contact lens.
(a)
Identification. A rigid gas permeable contact lens is a device intended to be worn directly against the cornea of the eye to correct vision conditions. The device is made of various materials, such as cellulose acetate butyrate, polyacrylate-silicone, or silicone elastomers, whose main polymer molecules generally do not absorb or attract water.(b)
Classification. (1) Class II if the device is intended for daily wear only.(2) Class III if the device is intended for extended wear.
(c)
Date PMA or notice of completion of a PDP is required. As of May 28, 1976, an approval under section 515 of the act is required before a device described in paragraph (b)(2) of this section may be commercially distributed. See § 886.3.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features the department's name encircling a stylized symbol. The symbol consists of three human profiles facing right, stacked on top of each other, with flowing lines extending from the bottom profile.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
April 27, 2016
Advanced Vision Technologies % Mr. Bret Andre Principal Consultant EyeReg Consulting, Inc. 6119 Canter Lane West Linn. OR 97068
Re: K152724
Trade/Device Name: EyePrintPRO (roflufocon D) Scleral GP Lenses Regulation Number: 21 CFR 886.5916 Regulation Name: Rigid Gas Permeable Contact Lens Regulatory Class: Class II Product Code: HQD Dated: March 15, 2016 Received: March 18, 2016
Dear Mr. Andre:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
1
forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"
(21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kesia Alexander
for Malvina B. Eydelman, M.D. Director Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K152724
Device Name EyePrintPRO (roflufocon D) Scleral GP Lenses
Indications for Use (Describe)
The EyePrintPRO (roflufocon D) Scleral GP Lenses are indicated for daily wear for the correction of refractive error in aphakic and not aphakic persons with myopia or hyperopia. The lenses may be prescribed in otherwise non-diseased eyes that require a rigid gas permeable lens for the management of irregular corneal conditions such as; keratoconus, pellucid marginal degeneration or following penetrating keratoplasty or refractive (e.g. LASIK) surgery.
Eyecare practitioners may prescribe the lenses for frequent/planned replacement wear, with cleaning, disinfection and scheduled replacement. When prescribed for frequent wear, the lens may be cleaned and disinfected using a chemical (not heat) lens care system.
Type of Use (Select one or both, as applicable)
2 Prescription Use (Part 21 CFR 801 Subpart D)
- Over-The-Counter Use (21 CFR 801 Subpart C)
PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON A SEPARATE PAGE IF NEEDED.
FOR FDA USE ONLY
Concurrence of Center for Devices and Radiological Health (CDRH) (Signature)
This section applies only to requirements of the Paperwork Reduction Act of 1995,
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW!
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510 (k) SUMMARY OF SAFETY AND EFFECTIVENESS
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
| The assigned 510(k) number is: | K152724 |
|---|---|
| Applicant information: | |
| Date Prepared: | April 25th, 2016 |
| Name: | Advanced Vision Technologies |
| 969 South Kipling Parkway | |
| Lakewood, CO 80226 | |
| United States | |
| Contact Person: | Keith Parker |
| Vice President | |
| Phone number: | (888) 393-5374 |
| Consultant: | Bret J Andre |
| EyeReg Consulting, Inc. | |
| 6119 Canter Ln. | |
| West Linn, OR 97068 | |
| United States | |
| Phone number: | (503) 372-5226 |
| Device Information: | |
| Device Classification: | Class II |
| Product Code: | HQD |
| Classification Name: | Lenses, Rigid Gas Permeable, Daily Wear (21 CFR 886.5916) |
| Trade Name: | EyePrintPRO (roflufocon D) Scleral GP Lenses |
4
Purpose for Submission:
~ Labeling Change ~
Equivalent Devices:
The EyePrintPRO (roflufocon D) Scleral GP Lenses are substantially equivalent to the following predicate devices:
Predicate devices:
Device Description:
The EvePrintPRO (roflufocon D) Scleral GP Lens is a rigid gas permeable (RGP) lens designed from measurements of the ocular surface obtained by the EyePrint Impression Process. The vinyl polysiloxane (VPS) impression material used for the EyePrint Impression process is Panasil Initial Contact Light, with 510(k) clearance under K083701. The lenses are manufactured from the hydrophobic contact lens material (roflufocon D). When placed on the human cornea, the EvePrintPRO RGP lenses act as a refracting medium to focus light rays upon the retina.
The EyePrintPRO (roflufocon D) Scleral GP Lenses are available as lathe cut lenses manufactured from (roflufocon D) optical blanks, which incorporate a handling tint using the following FDA listed color additives: D & C Green No. 6, FD & C Red No. 17, CI Solvent Yellow 18.
In the EyePrintPRO (roflufocon D) Scleral GP Lenses with UV Blocker, a Benzophenone UV absorbing monomer is used to block UV radiation. The UV Blocker is 2,2'-Dihydroxy-4,4'dimethoxybenzophenone.
The UV blocking for EyePrintPRO (roflufocon D) Scleral GP Lenses averages > 98% in the UVB range of 280nm - 315nm and 95% in the UVA range of 316 - 380nm.
The physical and mechanical properties of the lens are:
| Refractive Index | 1.4333 |
|---|---|
| Light Transmission (clear) | greater than 97% |
| Light Transmission (tinted) | greater than 90% |
| Wetting Angle | 3° |
| Specific Gravity | 1.166 |
| Oxygen Permeability | 100 x 10-11 (cm²/sec)(mlO₂)/(ml x mmHg @ 35°C) |
| Flexural Strength (Mpa) | 49.0 |
| Modulus (Mpa) | 76.7 |
| Shore D Hardness | 77.5 |
5
Packaging:
The EyePrintPRO (roflufocon D) Scleral GP Lens may be shipped "dry" or "wet" in a contact lens case. The primary container for shipping the EyePrintPRO (roflufocon D) Scleral GP Lens is the #750/750U by Pelican Products, Inc./Paragon Vision Sciences, with clearance under 510(k) K030987. The lens is shipped (wet) non-sterile in the OPTIMUM by Lobob Cleaning and Disinfecting Storage solution, with clearance under 510(k) K014162. The solution contains lauryl sulfate salt of imidazoline, octylphenoxy polyethoxyethanol and preserved with benzyl alcohol.
The EyePrintPRO (roflufocon D) Scleral GP Lenses are manufactured to the following specifications:
| Chord Diameter | 13.0 mm to 20.00 mm |
|---|---|
| Center Thickness | 0.25 mm to 0.90 mm |
| Base Curve | 6.0 mm to 10.0 mm |
| Power Range | -25.00D to +25.00D in 0.12 steps |
Indications for Use:
The EvePrintPRO (roflufocon D) Scleral GP Lenses are indicated for daily wear for the correction of refractive error in aphakic and not aphakic persons with myopia or hyperopia. The lenses may be prescribed in otherwise non-diseased eyes that require a rigid gas permeable lens for the management of irregular corneal conditions such as: keratoconus, pellucid marginal degeneration or following penetrating keratoplasty or refractive (e.g. LASIK) surgery.
Eyecare practitioners may prescribe the lenses for frequent/planned replacement wear, with cleaning, disinfection and scheduled replacement. When prescribed for frequent/planned replacement wear, the lens may be cleaned and disinfected using a chemical (not heat) lens care system.
Description of Safety:
The safety profile for finished contact lenses manufactured from (roflufocon D) may be referenced in 510(k) K033594. Additional studies were conducted to evaluate the safety and effectiveness of the EyePrintPRO (roflufocon D) Scleral GP Lenses. A summary of the results are presented below:
Bioburden
Bioburden testing was performed on rigid gas permeable lenses manufactured at the Advanced Vision Technologies facility. Testing resulted in less than 1 colony forming units (CFU) per lens. The acceptance criteria is less than 100 CFU per lens.
Clinical Evaluation of EyePrint Impression Process
Non-invasive tear break up time (NITBUT), ocular surface redness, and corneal staining were evaluated (n = 8) before and after the EyePrint Impression Process. No significant changes from baseline were observed
6
Conclusions Drawn from Studies
Studies presented demonstrate that the EyePrint Impression Process is safe for the ocular surface, and the EyePrintPRO (roflufocon D) Scleral GP Lenses are substantially equivalent and do not raise different questions of safety and effectiveness than the previously marketed OPTIMUM GP contact lenses (roflufocon D), 510(k) cleared under K070628 & K033594.
Substantial Equivalence:
The EyePrintPRO (roflufocon D) Scleral GP Lenses are identical to the predicate device in terms of contact lens material (roflufocon D). lathe cut manufacturing processes, and indications for use.
The EvePrintPRO (roflufocon D) Scleral GP Lenses are substantially equivalent and do not raise different questions of safety and effectiveness than the predicate device identified previously.
The following comparison table depicts characteristics of the EyePrintPRO (roflufocon D) contact lens, as well as the predicate device.
| | AVT
EyePrintPRO
Subject Device | Contamac ltd.
Optimum GP
Predicate Device |
|---------------------|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Functionality | Same as predicate device | After machining from the optical
blank, the contact lenses act as a
refractive medium that focus
light rays from near and distant
objects on the retina. |
| Indication for Use | Same as predicate device | Daily Wear, Rigid Gas
Permeable (RGP) Contact
Lenses |
| Production Method | Lathe-cut;
EyePrint Impression Process for
lens design specifications | Lathe-cut;
Corneal Topographer or
Keratometer readings for lens
design specifications |
| USAN name | Same as predicate device | roflufocon D |
| FDA Group # | Same as predicate device | Group # 3 Fluoro
Silicone Acrylate |
| Oxygen Permeability | Same as predicate device | $100 x 10^{-11} (cm^2/sec)(mlO_2)/(ml x mmHg @ 35°C)$ (revised Fatt
method) |
| Water Content (%) | Same as predicate device |